TRI-stent Adjudication Study - Low risk of Restenosis.

Trial Profile

TRI-stent Adjudication Study - Low risk of Restenosis.

Discontinued
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 30 Apr 2014

At a glance

  • Drugs Anti-CD34 monoclonal antibody (Primary) ; Paclitaxel; Sirolimus
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms TRIAS-LR
  • Most Recent Events

    • 21 Mar 2014 According to ISRCTN: Current Controlled Trials, status changed from recruiting to discontinued.
    • 09 Dec 2013 Planned end date changed from 1 Mar 2013 to 1 Feb 2019 as reported by ISRCTN: Current Controlled Trials.
    • 09 Dec 2013 Status changed from completed to recruiting as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top